AME Case Series Checklist –Adapted from CARE Checklist and PROCESS Checklist

Section	Item	Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title	1	The diagnosis or intervention of primary focus followed by the words “case series”.	Page 1/Line 3	Title part of Full Title
Key Words	2	2 to 5 key words that identify diagnoses or interventions in this case series, including "case report" or "case series".	Page 2/Line 36	Keywords of Full Title Page
Abstract (no references)	3a	Introduction—What is unique about this case series and what does it add to the scientific literature?	Page 3/Line 44-48	Abstract/Paragraph 1
	3b	Methods—describe what was done, how and when was it done and by whom.	Page 3/Line 49-54	Abstract/Paragraph 2
	3c	Results—what was found.	Page 3-4/Line 55-66 and	Abstract/Paragraph 3
	3d	Conclusion—What is the main take-away lesson(s)? What have we learned and what does it mean?	Page 5/Line 2	Abstract/Paragraph 4
Introduction	4	Explain the scientific background and rationale for the case series. What is the unifying theme - common disease, exposure, intervention and outcome, etc. Why is this study needed?	Page 6/Line 1-26	Introduction/Paragraph 1
Methods	5a	Registration and ethics— 5a.1 State the research registry number in accordance with the declaration of Helsinki - “Every research study involving human subjects must be registered in a publicly accessible database” (this can be obtained from; ResearchRegistry.com or ClinicalTrials.gov or ISRCTN). 5a.2 State whether ethical approval was passed. 5a.3 Provide the patient consent form too.	Page 7/Line 29-32	Methods/Paragraph 1
	5b	Study design—state the study is a case series and whether prospective or retrospective in design, whether single or multi-center and whether cases are consecutive or non-consecutive.	Page 7/Line 37	Methods/Paragraph 1
	5c	Setting - describe the setting(s)and nature of the institution in which the patient was managed; academic, community or private practice setting? Location(s), and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.	Page 7/Line 30	Methods/Paragraph 1
	5d	Participants— 5d.1 Describe the relevant characteristics of the participants (history, comorbidities, tumor staging, smoking, etc.). 5d.2 State any eligibility (inclusion/exclusion) criteria and the sources and methods of selection of participants.	Page 7/Line 32-35	Methods/Paragraph 1

	5e	Intervention—types of intervention (such as pharmacologic, surgical, preventive, self-care) deployed and reasoning behind treatment offered. Pharmacological therapies should include formulation, dosage, strength, route and duration.	This study is not involving intervention.	NA
	5f	Follow up—describe length and methods of follow-up.	This study is not involving	NA
Results	6a	Participants—reports numbers involved and their characteristics (comorbidities, tumor staging, smoking, etc.).	Page 9/Line 81	Results/Paragraph 1
	6b	Any changes in the interventions during the course of the case series (how has it evolved, been tinkered with, what learning occurred, etc.) together with rationale and a diagram if appropriate.	This study is not involving intervention.	NA
	6c	Outcomes and follow-up—Clinician assessed and patient-reported outcomes (when appropriate) should be stated with inclusion of the time periods at which assessed. Relevant photographs/radiological images should be provided. e.g. 12-month follow-up.	This study is not involving follow-up.	NA
	6d	Where relevant—intervention adherence/compliance and tolerability (how was this assessed). Describe loss to follow-up (express as a percentage) and any explanations for it.	This study is not involving intervention.	NA
	6e	Complications and adverse or unanticipated events.	There is no complications,	NA
Discussion	7a	Summarize key results.	Page 12-13/Line 129-157	Discussion/Paragraph 2
	7b	Discussion of the relevant literature, implications for clinical practice guidelines. How do outcomes compare with established therapies and the prevailing gold standard? Generate a hypothesis if possible.	Page 17/Line 233-238	Discussion/Paragraph 4
	7c	Strengths and limitations of the study.	Page 17/Line 245-249	Discussion/Paragraph 5
	7d	The rationale for any conclusions.	Page 11-16/Line 112-213	Discussion/Paragraph 1-3
Conclusion	8a	State the key conclusions from the study.	Page 17-18/Line 252-258	Conclusions/Paragraph 1
	8b	State what needs to be done next, further research with what study design.	Page 17/Line 245-249	Discussion/Paragraph 5

Article information: http://dx.doi.org/10.21037/gs-20-790.
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	There is no antibody used in the study.	n/a

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	There is no cell experiment in the study.	n/a
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	There is no experiment in the study.	n/a

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	There is no animal used in the study.	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	There is no animal used in the study.	n/a
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	There is no model organism in the study.	n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	There is no plant in the study.	n/a
Microbes: provide species and strain, unique accession number if available, and source	There is no experiment in the study.	n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes, it is provided at Methods and Footnote. (Methods/paragraph 1 or Footnote/ethical statement)	
Provide statement confirming informed consent obtained from study participants.	Yes, it is provided at Methods and Footnote. (Methods/paragraph 1 or Footnote/ethical statement)	
Report on age and sex for all study participants.	Yes, it is provided at Results (Results/paragraph 1)	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	It is not a clinical trial.	n/a

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	There is no such design in the study.	n/a

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	Yes, it is provided at Method (Methods/paragraph 1)	
Randomisation	There is no such experiment method in the study.	n/a
Blinding	There is no such experiment method in the study.	n/a
Inclusion/exclusion criteria	Yes, it is provided at Method (Methods/paragraph 1)	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	This study is an observational study, is not involving experiment.	n/a
Define whether data describe technical or biological replicates	This study is an observational study, is not involving experiment.	n/a

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes, it is provided at Methods and Footnote. (Methods/paragraph 1 or Footnote/ethical statement)	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	There is no animal used in the study.	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	This study is not involving specimen and field samples.	n/a

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	The study is not subject to dual use research of concern.	n/a

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	This study is not involving sample or data point exclusion.	n/a

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	This study is an observational study, is not involving statistical test.	n/a

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	The datasets used and/or analyzed during the current study are available on reasonable request.	n/a
If data are publicly available, provide accession number in repository or DOI or URL.	There is no accession number or DOI or URL.	n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	There is no accession number or DOI or URL.	n/a

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	This study is not involving any code.	n/a
If code is publicly available, provide accession number in repository, or DOI or URL.	This study is not involving any code.	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	Yes, ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/gs-20-790.